IP Verse

Antibodies And Vaccines For Use In Therapeutic And Diagnostic Methods For Alpha-Synuclein-Related Disorders - EP2282758

The patent EP2282758 was granted to Bioarctic on Nov 21, 2018. The application was originally filed on Apr 28, 2009 under application number EP09738534A. The patent is currently recorded with a legal status of "Revoked".

EP2282758

BIOARCTIC
Application Number
EP09738534A
Filing Date
Apr 28, 2009
Status
Revoked
Sep 19, 2024
Grant Date
Nov 21, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CARPMAELS & RANSFORD SPECIALITIESAug 21, 2019CARPMAELS & RANSFORDADMISSIBLE
UCB BIOPHARMAAug 21, 2019UCBADMISSIBLE
JAMES POOLEAug 16, 2019CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2005203010
INTERNATIONAL-SEARCH-REPORTUS2006018918
INTERNATIONAL-SEARCH-REPORTUS2006058233
INTERNATIONAL-SEARCH-REPORTUS2006259986
INTERNATIONAL-SEARCH-REPORTUS2008014194
INTERNATIONAL-SEARCH-REPORTWO0002053
INTERNATIONAL-SEARCH-REPORTWO2004041067
INTERNATIONAL-SEARCH-REPORTWO2005047860
INTERNATIONAL-SEARCH-REPORTWO2006020581
INTERNATIONAL-SEARCH-REPORTWO2006045037
INTERNATIONAL-SEARCH-REPORTWO2007089862
OPPOSITIONEP1578253
OPPOSITIONEP2539366
OPPOSITIONUS2008014194
OPPOSITIONWO2006045037
OPPOSITIONWO2007011907
OPPOSITIONWO2008103472
OPPOSITIONWO2010069603
OPPOSITIONWO2011104696
OTHERWO2006045037

Non-Patent Literature (NPL) Citations (87) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- TROSTCHANSKY ANDRÉS ET AL, "Interaction with phospholipids modulates alpha-synuclein nitration and lipid-protein adduct formation", BIOCHEMICAL JOURNAL, PORTLAND PRESS LTD, GB, (20060101), vol. 393, no. Pt 1, doi:10.1042/BJ20051277, ISSN 0264-6021, pages 343 - 349, XP002546324
EXAMINATION- SOUZA J M ET AL, "DITYROSINE CROSS-LINKING PROMOTES FORMATION OF STABLE ALPHA-SYNUCLEIN POLYMERS IMPLICATION OF NITRATIVE AND OXIDATIVE STRESS IN THE PATHOGENESIS OF NEURODEGENERATIVE SYNUCLEINOPATHIES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (20000616), vol. 275, no. 24, doi:10.1074/JBC.M000206200, ISSN 0021-9258, pages 18344 - 18349, XP001151969
INTERNATIONAL-SEARCH-REPORT- BEYER KATRIN ET AL, "The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, (200811), vol. 15, no. 26, ISSN 0929-8673, pages 2748 - 2759, XP009110439 [PY] 1-26 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- MAGUIRE-ZEISS KATHLEEN A ET AL, "HSV Amplicon Expression of Single Chain Antibodies Directed Against alpha-Synuclein Conformers", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY MAY 2004, (200405), vol. 9 Suppl 1, ISSN 1525-0016, pages S86 - S86, XP002566128 [A] 26-52 * Abstract 222 *-
INTERNATIONAL-SEARCH-REPORT- POUNTNEY DEAN L ET AL, "Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis.", NEUROTOXICITY RESEARCH 2005, (2005), vol. 7, no. 1-2, ISSN 1029-8428, pages 59 - 67, XP002546323 [A] 1-26 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MAGUIRE-ZEISS ET AL, "Identification of human alpha-synuclein specific single chain antibodies", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, (20061103), vol. 349, no. 4, ISSN 0006-291X, pages 1198 - 1205, XP005660723 [A] 26-52 * the whole document *
INTERNATIONAL-SEARCH-REPORT- NÄSSTRÖM TOMAS ET AL, "The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 23 JAN 2009, (20090123), vol. 378, no. 4, ISSN 1090-2104, pages 872 - 876, XP002546413 [DPY] 1-26 * the whole document *
INTERNATIONAL-SEARCH-REPORT- NANNENGA ET AL, "Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (20080128), vol. 582, no. 4, ISSN 0014-5793, pages 517 - 522, XP022473295 [A] 26-52 * the whole document *
INTERNATIONAL-SEARCH-REPORT- BERGSTROM J ET AL, "P2-218: Characterization of early events in the alpha-synuclein aggregation pathway", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 4, no. 4, ISSN 1552-5260, (20080701), page T435, (20080701), XP023174217 [PY] 1-26 * the whole document *
INTERNATIONAL-SEARCH-REPORT- WAHLBERG T ET AL, "P2-372: Development of oligomer-specific alpha-synuclein antibodies", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 4, no. 4, ISSN 1552-5260, (20080701), pages T481 - T482, (20080701), XP023174371 [PX] 26-52 * Abstract P2-372 *
INTERNATIONAL-SEARCH-REPORT- NASSTROM T ET AL, "P4-284: Oligomeric amorphous species of alpha-synuclein induce toxicity in a cellular model", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 4, no. 4, ISSN 1552-5260, (20080701), page T754, (20080701), XP023175257 [PY] 1-26 * abstract *
INTERNATIONAL-SEARCH-REPORT- EMADI ET AL, "Isolation of a Human Single Chain Antibody Fragment Against Oligomeric alpha-Synuclein that Inhibits Aggregation and Prevents alpha-Synuclein-induced Toxicity", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, (20070417), vol. 368, no. 4, ISSN 0022-2836, pages 1132 - 1144, XP022030022 [A] 26-52 * the whole document *
INTERNATIONAL-SEARCH-REPORT- LYNCH ET AL, "An scFv Intrabody against the Nonamyloid Component of alpha-Synuclein Reduces Intracellular Aggregation and Toxicity", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, (20071205), vol. 377, no. 1, ISSN 0022-2836, pages 136 - 147, XP022501449 [A] 26-52 * the whole document *
INTERNATIONAL-SEARCH-REPORT- ZHOU C ET AL, "A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, (20041201), vol. 10, no. 6, ISSN 1525-0016, pages 1023 - 1031, XP004651493 [A] 26-52 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MILLER ET AL, "Intrabody applications in neurological disorders: progress and future prospects", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, (20050901), vol. 12, no. 3, ISSN 1525-0016, pages 394 - 401, XP005472373 [A] 26-52 * the whole document *
INTERNATIONAL-SEARCH-REPORT- SHTILERMAN MARK D ET AL, "Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?", BIOCHEMISTRY 26 MAR 2002, (20020326), vol. 41, no. 12, ISSN 0006-2960, pages 3855 - 3860, XP002546412 [A] 1-26 * the whole document *
INTERNATIONAL-SEARCH-REPORT- EMADI SHARAREH ET AL, "Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 43, no. 10, ISSN 0006-2960, (20040316), pages 2871 - 2878, (20040220), XP002517647 [A] 26-52 * the whole document *
INTERNATIONAL-SEARCH-REPORT- TROSTCHANSKY ANDRÉS ET AL, "Interaction with phospholipids modulates alpha-synuclein nitration and lipid-protein adduct formation.", THE BIOCHEMICAL JOURNAL 1 JAN 2006, (20060101), vol. 393, no. Pt 1, ISSN 1470-8728, pages 343 - 349, XP002546324 [A] 1-26 * the whole document *
INTERNATIONAL-SEARCH-REPORT- LEE M ET AL, "Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult.", JOURNAL OF NEUROCHEMISTRY FEB 2001, (200102), vol. 76, no. 4, ISSN 0022-3042, pages 998 - 1009, XP002546325 [A] 1-26 * the whole document *
INTERNATIONAL-SEARCH-REPORT- DAVIDSON W S ET AL, "Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 17 APR 1998, (19980417), vol. 273, no. 16, ISSN 0021-9258, pages 9443 - 9449, XP002546326 [A] 1-26 * the whole document *
INTERNATIONAL-SEARCH-REPORT- QIN ZHIJIE ET AL, "Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 23 FEB 2007, (20070223), vol. 282, no. 8, ISSN 0021-9258, pages 5862 - 5870, XP002546322 [DY] 2-17,19-22 * the whole document *
INTERNATIONAL-SEARCH-REPORT- KOSTKA MARCUS ET AL, "Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 18 APR 2008, (20080418), vol. 283, no. 16, ISSN 0021-9258, pages 10992 - 11003, XP002566129 [A] 26-52 * the whole document *
INTERNATIONAL-SEARCH-REPORT- PAPACHRONI KATERINA K ET AL, "Autoantibodies to alpha-synuclein in inherited Parkinson's disease", JOURNAL OF NEUROCHEMISTRY, WILEY INTERSCIENCE, NEW YORK, NY, US, (20070501), vol. 101, no. 3, ISSN 0022-3042, pages 749 - 756, XP002530228 [A] 26-52 * the whole document *
OPPOSITION- "4-Hydroxynonenal Antibody Monoclonal Mouse IgG2B Clone # 198960 Catalog Number: MAB3249", R&D Systems, (20181204), pages 1 - 2, XP055651699-
OPPOSITION- "4-Hydroxynonenal Antibody", Screenshot, URL: https://www.rndsvstems.com/products/4-hydroxynonenal-antibody-198960_mab3249#product-citations-
OPPOSITION- "alpha-synuclein (211): sc-12767", Santa Cruz Biotechnology, page 1-
OPPOSITION- anonymous, "Decosohexanoic acid (DHA)", Tocris - Data sheet, (20181002), XP055637983-
OPPOSITION- "Anti 4-HNE monoclonal antibody (HNEJ-2)", jaica.com, URL: https://www.jaica.com/e/products_lipid_4hne_ab.html, XP055651742-
OPPOSITION- Baba M. et al, "AGGREGATION OF ALPHA-SYNUCLEIN IN LEWY BODIES OF SPORADIC PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES", American Journal of Pathology, (19980400), vol. 152, no. 4, pages 879 - 884, XP000940765-
OPPOSITION- Biochem J., (20060000), vol. 393, pages 343 - 349-
OPPOSITION- CREMADES N. et al., "Chapter Three - Structural Characteristics of α-Synuclein Oligomers", International Review of Cell and Molecular Biology, (20170000), vol. 329, pages 79 - 143, XP055637752-
OPPOSITION- "epigenics", Cosmo Bio News Topics Digest, (20040000), pages 1 - 77, XP055651411-
OPPOSITION- Experimental report for the 8A5 antibody-
OPPOSITION- FERNAGUT, "Behavioral and Histopathological Consequences of Paraquat Intoxication in Mice: Effects of α-Synuclein Over-Expression", NIH Public Access Author Manuscript, (20070000), vol. 61, no. 12, pages 1 - 19-
OPPOSITION- FJORBACK, "Determination of alpha-synuclein concentrationin human plasma using ELISA", Scandinavian Journal of Clinical & Laboratory Investigation, (20070000), vol. 67, pages 431 - 435-
OPPOSITION- Product sheet for deposited 8A5 antibody-producing cell line-
OPPOSITION- "Purified Mouse Anti-alpha-Synculein Clone 42/alpha-Synuclein (RUO)", BDBioSciences,, (2019), URL: https://www.bdbiosciences.com/eu/applications/research/stem-cell-research/ectoderm-markers/human/purified-mouse-anti--synuclein-42-synuclein/p/610786, XP055651463-
OPPOSITION- Screenshot, URL: http://dshb.biology.uiowa.edu/H3C-
OPPOSITION- Screenshot, URL: https://www.abcam.com/4-hvdroxynonena!-antibodv-hne!-2-ab48506- references. htm l-
OPPOSITION- "Technical Data Sheet Purified Mouse Anti-alpha-Synuclein", BD Transduction Laboratories, (2007), pages 1 - 2, XP055651472-
OPPOSITION- GIASSON B. I. ET AL, "A Panel of Epitope-Specific Antibodies Detects Protein Domains Distributed Throughout Human alpha-Synuclein in Lewy Bodies of Parkinson's Disease", Journal of Neuroscience Research, (20000200), vol. 59, pages 528 - 533, XP003016506
OPPOSITION- GOMEZ-TORTOSA, "α-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining", Acta Neuropathologica, (20000000), vol. 99, no. 4, pages 352 - 357, XP055651216
OPPOSITION- Bengoa-Vergniory et al., "Alpha-synuclein oligomers: a new hope", ACTA NEUROPATHOLOGICA, (20170000), vol. 134, pages 819 - 838, XP036351197
OPPOSITION- Shamoto-Nagai M. et al, "In parkinsonian substantia nigra, a-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity", J Neural Transm, (20070810), vol. 114, no. 12, pages 1559 - 1567, XP019565366
OPPOSITION- TOYOKUNI, "The monoclonal antibody specific for the 4-hydroxy-2- nonenal histidine adduct", FEBS Letters, (19950000), vol. 359, pages 189 - 191, XP002498917
OPPOSITION- GEORGE et al., "Characterization of a novel protein regulated during the critical period for song learning in the zebra finch", Neuron, (19950000), vol. 15, pages 361 - 372, XP055638011
OPPOSITION- ulia M. George et al, "Characterization of a Novel Protein Regulated during the Critical Period for Song Learning in the Zebra Finch", Neuron, (19950800), vol. 15, no. 2, pages 361 - 372, XP055638011
OPPOSITION- MAGUIRE-ZEISS et al., "Identification of human alpha-synuclein specific single chain antibodies", BBRC, (20061103), vol. 349, no. 4, pages 1198 - 1205, XP024924560
OPPOSITION- NASSTROM, "The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links @a-synuclein causing rapid formation of stable oligomers", Biochemical and Biophysical Research Communications, (20090000), vol. 378, pages 872 - 876, XP025841513
OPPOSITION- NÄSSTRÖM et al., BBRC, (20090123), vol. 378, no. 4, pages 872 - 876, XP002546413
OPPOSITION- CREMADES et al., "Direct Observation of the Interconversion of Normal and Toxic Forms of ex-Synuclein", Cell, (20120500), vol. 149, no. 5, pages 1048 - 59, XP055637750
OPPOSITION- ALMANDOZ-GIL, "Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways", Free Radical Biology and Medicine, (20170000), vol. 110, pages 421 - 431, XP085143619
OPPOSITION- WAHLBERG et al., Alzheimer's and dementia, (20080701), vol. 4, no. 4, pages T481 - T482, XP023174371
OPPOSITION- EMADI et al., "Isolation of a human single chain antibody fragment against oligomeric a:-synuclein that inhibits aggregation and prevents a 一 synuclein induced toxicity", Journal of Molecular Biology, (20070417), vol. 368, no. 4, pages 1132 - 114, XP022030022
OPPOSITION- MASLIAH et al., "Effects of alpha-synuclein immunization in a mouse model of Parkinsons disease", Neuron, (20050616), vol. 46, no. 6, doi:10.1016/j.neuron.2005.05.010, pages 857 - 868, XP008091682
OPPOSITION- SHARMA, "A close association of torsinA and alpha-synuclein in Lewy bodies: A fluorescence resonance energy transfer study", American Journal of Pathology, (20010000), vol. 159, no. 1, pages 339 - 344, XP002592064
OPPOSITION- JAKES R.et al, "Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein", Neuroscience Letters, (19990701), vol. 269, pages 13 - 16, XP003016505
OPPOSITION- Ronit Sharon et al, "The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.", Neuron, (20030220), vol. 37, no. 4, pages 583 - 595, XP055481874
OPPOSITION- SHARON, "The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease", Neuron, (20030000), vol. 37, pages 583 - 595, XP055481874
OPPOSITION- CONWAY et al., "Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease", Nature Medicine, (19980000), vol. 4, no. 11, pages 1318 - 1320, XP002283512
OPPOSITION- TROSTCHANSKY et al., "Interaction with phospholipids modulates alpha-synuclein nitration and lipid-protein adduct formation", Biochemical Journal, (20060100), vol. 393, no. Pt 1, pages 343 - 349, XP002546324
OPPOSITION- KAWAMATA, "Interaction of α-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations : α-Synuclein and synphilin-1 interactions", Journal of Neurochemistry, (20010000), vol. 77, pages 929 - 934, XP055651178
OPPOSITION- SERPELL, "Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross deta conformation", PNAS, (20000000), vol. 97, no. 9, pages 4897 - 4902, XP055637987
OPPOSITION- JENSEN, "α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356*", The Journal of Biological Chemistry, (19990000), vol. 274, no. 36, pages 25481 - 25489, XP002947238
OPPOSITION- MCLEAN et al., "Membrane Association and Protein Conformation of ␣-Synuclein in Intact Neurons EFFECT OF PARKINSONЈS DISEASE-LINKED MUTATIONS", The Journal of Biological Chemistry, (20000000), vol. 275, no. 12, pages 8812 - 8816, XP055651149
OPPOSITION- JENSEN, "Microtubule-associated Protein 1B Is a Component of Cortical Lewy Bodies and Binds α-Synuclein Filaments", Journal of Biological Chemistry, (20000000), vol. 275, no. 28, pages 21500 - 21507, XP055651527
OPPOSITION- SOUZA J.M. ET AL, "DITYROSINE CROSS-LINKING PROMOTES FORMATION OF STABLE ALPHA-SYNUCLEIN POLYMERS IMPLICATION OF NITRATIVE AND OXIDATIVE STRESS IN THE PATHOGENESIS OF NEURODEGENERATIVE SYNUCLEINOPATHIES", JBC, (20000616), vol. 275, no. 24, pages 18344 - 18349, XP001151969
OPPOSITION- Cole N. B. et al, "Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein a-Synuclein", JBC, (20020222), vol. 277, no. 8, pages 6344 - 6352, XP055637997
OPPOSITION- QIN et al., "Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation", Journal of Biochemistry, (20070223), vol. 282, no. 8, pages 5862 - 5870, XP002546322
OPPOSITION- QIN et al., "Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation", Journal of Biological Chemistry, (20070000), vol. 282, no. 8, pages 5862 - 5870, XP002546322
OPPOSITION- VOGIATZI, "Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells", The Journal of Biological Chemistry, (20080000), vol. 283, no. 35, pages 23542 - 23556, XP055651370
OPPOSITION- BAE, "Lipid Peroxidation Product 4-Hydroxy-2-Nonenal Promotes Seeding-Capable Oligomer Formation and Cell-to-Cell Transfer of α-Synuclein", Antioxidants & Redox Signaling, (20130000), vol. 18, no. 7, pages 770 - 783, XP055651810
OPPOSITION- Schneider B. L. et al, "Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation", Human Molecular Genetics, (20070219), vol. 16, no. 6, pages 651 - 666, XP055637783
OPPOSITION- SEO, "α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway", FASEB Journal, (20020000), XP055651673
OPPOSITION- EL-AGNAF et al., "α-Synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma", The FASEB Journal express article, vol. 17, (20030000), pages 16pp - 1947, URL: https://www.fasebj.org/doi/pdf/10.1096/fj.03-0098fje, XP055651350
OPPOSITION- RUESINK, "Stabilization of alpha-synuclein oligomers using formaldehyde", bioRxiv, (20190000), doi:10.1101/623538, XP055651524
OPPOSITION- FAGERQVIST, "Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation", Journal of Neurochemistry, (20130000), vol. 126, pages 131 - 144, XP055399050
OPPOSITION- Shinichi ASANO, "Aging influences multiple indices of oxidative stress in the heart of the Fischer 344/NNia x Brown Norway/BiNia rat. (Thesis)", Theses, (20070000), pages I - 81, XP055651807
OPPOSITION- MARGUTTI, "Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis", Blood, (20070000), vol. 111, no. 9, pages 4559 - 4570, XP055651709
OPPOSITION- NASSTROM, "Use of Recombinant Adenovirus Vectored Consensus IFN-α to Avert Severe Arenavirus Infection", PLoS ONE, (20110000), vol. 6, no. 10, pages 1 - 8, XP055309839
OPPOSITION- VAN DIGGELEN, "Two conformationally distinct α-synuclein oligomers share common epitopes and the ability to impair long-term potentiation", PLoS ONE, (20190000), vol. 14, no. 3, pages 1 - 22, XP055651430
OPPOSITION- LEE, "Intravesicular Localization and Exocytosis of a-Synuclein and its Aggregates", The Journal of Neuroscience, (20050000), vol. 25, no. 25, pages 6016 - 6024, XP055632575
OPPOSITION- VAN DER PUTTEN, "Neuropathology in mice expressing human alpha-synuclein", Journal of Neuroscience, (20000000), vol. 20, no. 16, pages 6021 - 6029, XP002983611
OPPOSITION- DANZER, "Different Species of -Synuclein Oligomers Induce Calcium Influx and Seeding", Journal of Neuroscience, (20070000), vol. 27, no. 34, pages 9220 - 9232, XP055651530
OPPOSITION- ASSAYAG, "Polyunsaturated Fatty Acids Induce α-Synuclein-Related Pathogenic Changes in Neuronal Cells", American Journal of Pathology, (20070000), vol. 171, no. 6, pages 2000 - 2011, XP055651334
OTHER- TROSTCHANSKV A. et al., "Interaction with phospholipids modulates alpha-synuclein nitration and lipid-protein adduct formation", Biochemical Journal,, (20060000), vol. 393, no. Pt 1, pages 343 - 349, XP002546324
OTHER- SOUZA JM. et al., "DITYROSINE CROSS-LINKING PROMOTES FORMATION OF STABLE ALPHA-SYNUCLEIN POLYMERS IMPLICATION OF NITRATIVE AND OXIDATIVE STRESS IN THE PATHOGENESIS OF NEURODEGENERATIVE SYNUCLEINOPATHIES", Journal of Biological Chemistry,, (20000000), vol. 275, no. 24, pages 18344 - 18349, XP001151969

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents